slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 67,261-67,290
Pages 3,679
Rows per page 30
Component
67,261-67,290 of 110,355
12
The slide uses a split-layout: left side defines the disease burden and market opportunity, right side defines the drug mechanism and target patient population.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
15
The slide uses a list-based structure to demonstrate the efficacy and speed of the AI platform, supported by external validation from The Lancet and Eli Lilly.BenevolentAI | Investor Conference Presentation Deck | 17 slides · BenevolentAI
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
06
The chart uses bubble size to represent market size. The matrix quadrants are labeled 'Remain Opportunistic' and 'Develop Portfolio'.Benson Hill | Results Presentation Deck | 24 slides · Benson Hill
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
24
This appears to be a background or transition slide showing the company's core technology (Berkeley Lights microfluidic platform).Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations 1 hit
27
The slide highlights the efficiency of the Beacon System in identifying rare, high-value antibodies compared to a known therapeutic benchmark.Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Need1 hit
39
The chart uses a stair-step visualization to show the transition from 'Manufacturable Today' to 'Not Manufacturable Today' based on dose and population size.Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations 1 hit
41
The slide contains no text other than the copyright notice and logo in the bottom left corner.Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations 1 hit
57
The slide uses a structured layout to connect problem, solution, and business impact.Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
59
Uses a 'multiplication' visual metaphor (Patient volume x COGS per dose = COGS reduction) to illustrate value.Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
71
The chart displays 23 bars representing quarterly data points, with specific values labeled for select periods.Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · SatisfactionLoop · Quick Win Big Bet1 hit
85
The slide uses bar charts to show historical data (2018-2021) and projections (2022, 2025).Berkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
90
Berkeley Lights | Investor Day Presentation Deck | 91 slidesBerkeley Lights | Investor Day Presentation Deck | 91 slides · Berkeley Lights
Conference presentation Investor relations Beat · Action1 hit
05
Uses a visual comparison framework to contrast healthy cells (no binding) vs cancer cells (binding).BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
The slide uses a Gantt-style visualization to show the clinical stage of drug candidates.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a structured list format to contrast the specific opportunity in UPS with the broader landscape of other sarcoma subtypes.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · Market Size1 hit
11
The slide uses a hierarchical tree structure to map patient cohorts to their respective clinical outcomes and advancement decisions.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
13
Includes specific clinical trial safety metrics (AEs, SAEs, CTCAE grades).BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
15
The slide uses a 2x2 grid of metrics to frame the market opportunity, followed by specific target population and success threshold data.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
Data cut-off Oct 28, 2022. Includes definitions for W/D, NSQ, SQ, and response markers.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
20
Data presented in a table format comparing BA3011 (N=13) and BA3011 + Opdivo (N=9).BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
23
The chart is a waterfall plot showing percentage change in tumor size for individual patients.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
24
The slide uses a 2x2 grid of metrics to frame the market problem, followed by specific target population sizing.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
25
The chart displays longitudinal data for two specific patients, showing sustained complete response.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
26
The slide uses a combination of big numbers and bulleted lists to frame the market opportunity and clinical unmet need.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
28
The slide uses a process-flow layout to describe clinical trial progression.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
30
The slide uses a combination of a comparison table for clinical data and a dot plot for NHP toxicity data.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
31
The slide uses a timeline-based visualization to show dose escalation steps. RP2D = Recommended Phase 2 Dose. DLT = Dose Limiting Toxicity.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
33
Uses a before-after-bridge style framing (problem on left, solution/results on right).BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
35
The slide uses a table-based timeline format to map specific clinical trial phases to programs and indications.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
39
Includes a Kaplan-Meier survival curve and a summary table of clinical outcomes.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit